author-photo

H. Marijke van den Berg

Utrecht University

56

Papers

3531

Citations

Citation Trend

Filter By

Papers (46) Sort By

Journal Conference Others

Capturing Data in Rare Disease Registries to Support Regulatory Decision Making: A Survey Study Among Industry and Other Stakeholders.

2021 Drug Safety
Show All
- Source
- Cite
- Save
Citations (1)
Inhibitor development in previously untreated patients with severe haemophilia: A comparison of included patients and outcomes between a clinical study and a registry-based study.

2020 Haemophilia
Show All
- Source
- Cite
- Save
Citations (0)
WFH Guidelines for the Management of Hemophilia, 3rd edition.

2020 Haemophilia
Show All
- Source
- Cite
- Save
Citations (192)
ITI Treatment is not First-Choice Treatment in Children with Hemophilia A and Low-Responding Inhibitors: Evidence from a PedNet Study.

2020 Thrombosis and Haemostasis
Show All
- Source
- Cite
- Save
Citations (2)
Timing of inhibitor development in >1000 previously untreated patients with severe hemophilia A

2019 Blood
Show All
- Source
- Cite
- Save
Citations (25)
Drug Registries and Approval of Drugs: Promises, Placebo, or a Real Success?

2018 Clinical Therapeutics
Show All
- Source
- Cite
- Save
Citations (2)
Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors

2017 Thrombosis and Haemostasis
Show All
- Source
- Cite
- Save
Citations (8)
Registries supporting new drug applications

2017 Pharmacoepidemiology and Drug Safety
Show All
- Source
- Cite
- Save
Citations (13)
Preventing bleeds by treatment: new era for haemophilia changing the paradigm

2016 Haemophilia
- H. Marijke van den Berg
Show All
- Source
- Cite
- Save
Citations (5)
Increased inhibitor incidence in severe haemophilia A since 1990 attributable to more low titre inhibitors.

2015 Thrombosis and Haemostasis
Show All
- Source
- Cite
- Save
Citations (15)